4Lowe V J, Fletcher JW, Gobar L, et al. Prospective investigation of PET in lung nodules. J Clin Oncol, 1998, 16: 1075-1084.
5Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographic s, 2003,23: 315-340.
6Rohren EM, Turkington TG, Edward RC. Clinical applications of PET in oncology. Radiology, 2004, 231: 305-332.
7Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a Meta-analysis. JAMA, 2001, 285: 914-924.
8Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated position emission tomography and computed tomography. N Engl J Med, 2003, 348: 2500-2507.
9Michael K, Gould MK, Gillian D, et al, Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules.Ann Intern Med, 2003, 138: 1724-1772.
10Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med, 2000, 343: 254-261.
4Szturz P,Hehák Z,KoukalováR,et al.Measuring diffuse metabolic activity on FDG-PET/CT:New method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma[J].Nuclear Medicine and Biology,2012,39(3):429-436.
